CSD241701

CSD241701 is an investigational drug candidate developed by Reynolds American, a subsidiary of British American Tobacco (BAT). It is currently being evaluated in a first-in-human Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetic profile in healthy volunteers. While specific details regarding its chemical structure and primary therapeutic indication are restricted due to a deferred public release of the trial protocol (approved by the UK Health Research Authority), the developer's focus suggests the compound is likely a novel nicotine replacement therapy (NRT) or a nicotinic receptor agonist intended for smoking cessation or tobacco harm reduction. The study (REC reference 23/SC/0344) utilizes a randomized, double-blind, placebo-controlled, single-ascending dose design.